 |
市場調查報告書
商品編碼
1413670
馮維勒布蘭德疾病治療藥物市場：按疾病類型、治療方法和給藥途徑分類 - 全球預測 2024-2030 年Von Willebrand Disease Treatment Market by Disease Type (Acquired VWD, Type 1, Type 2), Treatment (Clot-Stabilizing, Desmopressin, Replacement Therapies), Route of Administration - Global Forecast 2024-2030 |
||||||
價格
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
馮維樂布蘭氏症治療市場規模預估2023年為6.5312億美元，預計2024年將達7.1876億美元，複合年成長率為11.30%，2030年將達13.8212億美元。
馮維勒布蘭氏症藥物的全球市場
| 主要市場統計 | |
|---|---|
| 基準年[2023] | 6.5312 億美元 |
| 預測年份 [2024] | 71876萬美元 |
| 預測年份 [2030] | 1,382.12 百萬美元 |
| 複合年成長率（%） | 11.3% |
FPNV定位矩陣
FPNV定位矩陣對於評估馮維勒布蘭氏症藥物市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。
市場佔有率分析
市場佔有率分析是一種綜合工具，可以對血管性血友病治療藥物市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴考察，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。
本報告在以下方面提供了寶貴的見解：
1-市場滲透率：提供有關主要企業所服務的市場的全面資訊。
2-市場開拓：我們深入研究利潤豐厚的新興市場，並分析它們在成熟細分市場中的滲透率。
3- 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。
4-競爭力評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。
5- 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。
本報告解決了以下關鍵問題：
1-血管性血友病治療藥物市場的市場規模和預測是多少？
2-在馮維勒布蘭德疾病治療藥物市場的預測期內，有哪些產品、細分市場、應用和領域需要考慮投資？
3-血管性血友病藥物市場的技術趨勢和法律規範是什麼？
4-血管性血友病治療藥物市場主要供應商的市場佔有率是多少？
5-進入血管性血友病藥物市場的合適型態和策略手段是什麼？
目錄
第1章 前言
第2章調查方法
第3章執行摘要
第4章市場概況
第5章市場洞察
- 市場動態
- 促進因素
- 患有馮維勒布蘭氏症的人數不斷增加
- 患者援助計劃增加和醫療費用上漲
- 政府努力提高創新治療方法的有效性和成功率
- 抑制因素
- 與馮維勒布蘭氏症藥物相關的高成本
- 機會
- 馮維勒布蘭氏症治療產品核可數量增加
- 持續開發治療馮維樂布蘭氏症的新治療方法和診斷工具
- 任務
- 對血管性血友病藥物缺乏認知
- 促進因素
- 市場區隔分析
- 市場趨勢分析
- 高通膨的累積效應
- 波特五力分析
- 價值鍊和關鍵路徑分析
- 法律規範
第6章馮維勒布蘭德疾病治療藥物市場：依疾病類型
- 獲得 VWD
- 類型1
- 2型
- 類型3
第7章 馮維樂布蘭氏症藥物市場（按治療）
- 穩定血栓
- 去氨加壓素
- 替代療法
第8章馮維勒布蘭德疾病治療藥物市場：依給藥途徑
- 注射
- 口服
第9章：美洲血管性血友病藥物市場
- 阿根廷
- 巴西
- 加拿大
- 墨西哥
- 美國
第10章亞太地區血管性血友病藥物市場
- 澳洲
- 中國
- 印度
- 印尼
- 日本
- 馬來西亞
- 菲律賓
- 新加坡
- 韓國
- 台灣
- 泰國
- 越南
第11章 歐洲、中東和非洲馮維勒布蘭德病藥物市場
- 丹麥
- 埃及
- 芬蘭
- 法國
- 德國
- 以色列
- 義大利
- 荷蘭
- 奈及利亞
- 挪威
- 波蘭
- 卡達
- 俄羅斯
- 沙烏地阿拉伯
- 南非
- 西班牙
- 瑞典
- 瑞士
- 土耳其
- 阿拉伯聯合大公國
- 英國
第12章競爭形勢
- FPNV定位矩陣
- 市場佔有率分析：主要企業
- 主要企業競爭情境分析
第13章競爭產品組合
- 主要公司簡介
- Accredo Health Group, Inc.
- Affinity Biologicals Incorporated
- ARUP Laboratories
- AstraZeneca PLC
- Baxter Healthcare Corporation
- Bayer AG
- Bio Products Laboratory Ltd.
- Biogen Inc.
- Bristol Myers Squibb
- CSL Limited
- F. Hoffmann-La Roche AG
- Ferring Pharmaceuticals Inc
- Genentech Inc.
- Grifols, SA
- Laboratory Corporation of America Holdings
- Novo Nordisk A/S
- Octapharma AG
- Pfizer Inc.
- Sanofi SA
- Siemens Healthcare GmbH
- Sun Pharmaceutical Industries Limited
- Takeda Pharmaceutical Company Limited
- Thermo Fisher Scientific Inc.
- 主要產品系列
第14章附錄
- 討論指南
- 關於許可證和定價
Product Code: MRR-B168537791E6
[191 Pages Report] The Von Willebrand Disease Treatment Market size was estimated at USD 653.12 million in 2023 and expected to reach USD 718.76 million in 2024, at a CAGR 11.30% to reach USD 1,382.12 million by 2030.
Global Von Willebrand Disease Treatment Market
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2023] | USD 653.12 million |
| Estimated Year [2024] | USD 718.76 million |
| Forecast Year [2030] | USD 1,382.12 million |
| CAGR (%) | 11.3% |
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Von Willebrand Disease Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Von Willebrand Disease Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Von Willebrand Disease Treatment Market, highlighting leading vendors and their innovative profiles. These include Accredo Health Group, Inc., Affinity Biologicals Incorporated, ARUP Laboratories, AstraZeneca PLC, Baxter Healthcare Corporation, Bayer AG, Bio Products Laboratory Ltd., Biogen Inc., Bristol Myers Squibb, CSL Limited, F. Hoffmann-La Roche AG, Ferring Pharmaceuticals Inc, Genentech Inc., Grifols, S.A., Laboratory Corporation of America Holdings, Novo Nordisk A/S, Octapharma AG, Pfizer Inc., Sanofi S.A., Siemens Healthcare GmbH, Sun Pharmaceutical Industries Limited, Takeda Pharmaceutical Company Limited, and Thermo Fisher Scientific Inc..
Market Segmentation & Coverage
This research report categorizes the Von Willebrand Disease Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:
- Disease Type
- Acquired VWD
- Type 1
- Type 2
- Type 3
- Treatment
- Clot-Stabilizing
- Desmopressin
- Replacement Therapies
- Route of Administration
- Injection
- Oral
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
The report offers valuable insights on the following aspects:
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
1. What is the market size and forecast of the Von Willebrand Disease Treatment Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Von Willebrand Disease Treatment Market?
3. What are the technology trends and regulatory frameworks in the Von Willebrand Disease Treatment Market?
4. What is the market share of the leading vendors in the Von Willebrand Disease Treatment Market?
5. Which modes and strategic moves are suitable for entering the Von Willebrand Disease Treatment Market?
Table of Contents
1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
- 4.1. Introduction
- 4.2. Von Willebrand Disease Treatment Market, by Region
5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Rise in the number of people suffering from Von Willebrand disease
- 5.1.1.2. Increase in patient assistance programs and growing healthcare expenditure
- 5.1.1.3. Government initiatives to increase the efficacy and success rates of innovative treatments
- 5.1.2. Restraints
- 5.1.2.1. High cost associated with Von Willebrand disease treatment
- 5.1.3. Opportunities
- 5.1.3.1. Increasing number of product approvals for Von Willebrand disease treatment
- 5.1.3.2. Ongoing development of new treatments and diagnostic tools for Von Willebrand disease treatment
- 5.1.4. Challenges
- 5.1.4.1. Lack of awareness related to Von Willebrand disease treatment
- 5.1.1. Drivers
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
6. Von Willebrand Disease Treatment Market, by Disease Type
- 6.1. Introduction
- 6.2. Acquired VWD
- 6.3. Type 1
- 6.4. Type 2
- 6.5. Type 3
7. Von Willebrand Disease Treatment Market, by Treatment
- 7.1. Introduction
- 7.2. Clot-Stabilizing
- 7.3. Desmopressin
- 7.4. Replacement Therapies
8. Von Willebrand Disease Treatment Market, by Route of Administration
- 8.1. Introduction
- 8.2. Injection
- 8.3. Oral
9. Americas Von Willebrand Disease Treatment Market
- 9.1. Introduction
- 9.2. Argentina
- 9.3. Brazil
- 9.4. Canada
- 9.5. Mexico
- 9.6. United States
10. Asia-Pacific Von Willebrand Disease Treatment Market
- 10.1. Introduction
- 10.2. Australia
- 10.3. China
- 10.4. India
- 10.5. Indonesia
- 10.6. Japan
- 10.7. Malaysia
- 10.8. Philippines
- 10.9. Singapore
- 10.10. South Korea
- 10.11. Taiwan
- 10.12. Thailand
- 10.13. Vietnam
11. Europe, Middle East & Africa Von Willebrand Disease Treatment Market
- 11.1. Introduction
- 11.2. Denmark
- 11.3. Egypt
- 11.4. Finland
- 11.5. France
- 11.6. Germany
- 11.7. Israel
- 11.8. Italy
- 11.9. Netherlands
- 11.10. Nigeria
- 11.11. Norway
- 11.12. Poland
- 11.13. Qatar
- 11.14. Russia
- 11.15. Saudi Arabia
- 11.16. South Africa
- 11.17. Spain
- 11.18. Sweden
- 11.19. Switzerland
- 11.20. Turkey
- 11.21. United Arab Emirates
- 11.22. United Kingdom
12. Competitive Landscape
- 12.1. FPNV Positioning Matrix
- 12.2. Market Share Analysis, By Key Player
- 12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
- 13.1. Key Company Profiles
- 13.1.1. Accredo Health Group, Inc.
- 13.1.2. Affinity Biologicals Incorporated
- 13.1.3. ARUP Laboratories
- 13.1.4. AstraZeneca PLC
- 13.1.5. Baxter Healthcare Corporation
- 13.1.6. Bayer AG
- 13.1.7. Bio Products Laboratory Ltd.
- 13.1.8. Biogen Inc.
- 13.1.9. Bristol Myers Squibb
- 13.1.10. CSL Limited
- 13.1.11. F. Hoffmann-La Roche AG
- 13.1.12. Ferring Pharmaceuticals Inc
- 13.1.13. Genentech Inc.
- 13.1.14. Grifols, S.A.
- 13.1.15. Laboratory Corporation of America Holdings
- 13.1.16. Novo Nordisk A/S
- 13.1.17. Octapharma AG
- 13.1.18. Pfizer Inc.
- 13.1.19. Sanofi S.A.
- 13.1.20. Siemens Healthcare GmbH
- 13.1.21. Sun Pharmaceutical Industries Limited
- 13.1.22. Takeda Pharmaceutical Company Limited
- 13.1.23. Thermo Fisher Scientific Inc.
- 13.2. Key Product Portfolio
14. Appendix
- 14.1. Discussion Guide
- 14.2. License & Pricing
LIST OF FIGURES
- FIGURE 1. VON WILLEBRAND DISEASE TREATMENT MARKET RESEARCH PROCESS
- FIGURE 2. VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, 2023 VS 2030
- FIGURE 3. VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. VON WILLEBRAND DISEASE TREATMENT MARKET DYNAMICS
- FIGURE 7. VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
- FIGURE 8. VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
- FIGURE 10. VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
- FIGURE 12. VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 14. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 16. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. ASIA-PACIFIC VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 18. ASIA-PACIFIC VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. EUROPE, MIDDLE EAST & AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 20. EUROPE, MIDDLE EAST & AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 21. VON WILLEBRAND DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 22. VON WILLEBRAND DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
LIST OF TABLES
- TABLE 1. VON WILLEBRAND DISEASE TREATMENT MARKET SEGMENTATION & COVERAGE
- TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
- TABLE 3. VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
- TABLE 4. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
- TABLE 5. VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 6. VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ACQUIRED VWD, BY REGION, 2018-2030 (USD MILLION)
- TABLE 7. VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 1, BY REGION, 2018-2030 (USD MILLION)
- TABLE 8. VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2, BY REGION, 2018-2030 (USD MILLION)
- TABLE 9. VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 3, BY REGION, 2018-2030 (USD MILLION)
- TABLE 10. VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 11. VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CLOT-STABILIZING, BY REGION, 2018-2030 (USD MILLION)
- TABLE 12. VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DESMOPRESSIN, BY REGION, 2018-2030 (USD MILLION)
- TABLE 13. VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REPLACEMENT THERAPIES, BY REGION, 2018-2030 (USD MILLION)
- TABLE 14. VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 15. VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
- TABLE 16. VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
- TABLE 17. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 18. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 19. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 20. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 21. ARGENTINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 22. ARGENTINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 23. ARGENTINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 24. BRAZIL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 25. BRAZIL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 26. BRAZIL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 27. CANADA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 28. CANADA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 29. CANADA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 30. MEXICO VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 31. MEXICO VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 32. MEXICO VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 33. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 34. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 35. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 36. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
- TABLE 37. ASIA-PACIFIC VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 38. ASIA-PACIFIC VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 39. ASIA-PACIFIC VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 40. ASIA-PACIFIC VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 41. AUSTRALIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 42. AUSTRALIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 43. AUSTRALIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 44. CHINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 45. CHINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 46. CHINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 47. INDIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 48. INDIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 49. INDIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 50. INDONESIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 51. INDONESIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 52. INDONESIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 53. JAPAN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 54. JAPAN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 55. JAPAN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 56. MALAYSIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 57. MALAYSIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 58. MALAYSIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 59. PHILIPPINES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 60. PHILIPPINES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 61. PHILIPPINES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 62. SINGAPORE VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 63. SINGAPORE VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 64. SINGAPORE VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 65. SOUTH KOREA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 66. SOUTH KOREA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 67. SOUTH KOREA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 68. TAIWAN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 69. TAIWAN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 70. TAIWAN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 71. THAILAND VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 72. THAILAND VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 73. THAILAND VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 74. VIETNAM VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 75. VIETNAM VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 76. VIETNAM VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 77. EUROPE, MIDDLE EAST & AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 78. EUROPE, MIDDLE EAST & AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 79. EUROPE, MIDDLE EAST & AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 80. EUROPE, MIDDLE EAST & AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 81. DENMARK VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 82. DENMARK VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 83. DENMARK VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 84. EGYPT VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 85. EGYPT VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 86. EGYPT VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 87. FINLAND VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 88. FINLAND VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 89. FINLAND VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 90. FRANCE VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 91. FRANCE VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 92. FRANCE VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 93. GERMANY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 94. GERMANY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 95. GERMANY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 96. ISRAEL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 97. ISRAEL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 98. ISRAEL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 99. ITALY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 100. ITALY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 101. ITALY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 102. NETHERLANDS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 103. NETHERLANDS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 104. NETHERLANDS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 105. NIGERIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 106. NIGERIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 107. NIGERIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 108. NORWAY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 109. NORWAY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 110. NORWAY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 111. POLAND VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 112. POLAND VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 113. POLAND VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 114. QATAR VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 115. QATAR VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 116. QATAR VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 117. RUSSIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 118. RUSSIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 119. RUSSIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 120. SAUDI ARABIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 121. SAUDI ARABIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 122. SAUDI ARABIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 123. SOUTH AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 124. SOUTH AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 125. SOUTH AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 126. SPAIN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 127. SPAIN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 128. SPAIN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 129. SWEDEN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 130. SWEDEN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 131. SWEDEN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 132. SWITZERLAND VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 133. SWITZERLAND VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 134. SWITZERLAND VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 135. TURKEY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 136. TURKEY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 137. TURKEY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 138. UNITED ARAB EMIRATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 139. UNITED ARAB EMIRATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 140. UNITED ARAB EMIRATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 141. UNITED KINGDOM VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 142. UNITED KINGDOM VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 143. UNITED KINGDOM VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 144. VON WILLEBRAND DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
- TABLE 145. VON WILLEBRAND DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
- TABLE 146. VON WILLEBRAND DISEASE TREATMENT MARKET LICENSE & PRICING
02-2729-4219
+886-2-2729-4219
馮維勒布蘭德病(VWD)治療市場規模、市場份額、應用分析、區域展望、增長趨勢、主要參與者、競爭戰略和預測，2023-2031年
後天性類血友病病(AvWD)治療的全球市場 - 成長，未來預測，競爭分析(2022年～2030年)